The study is being published the week of June 18, 2007 in an advanced online edition of the Proceedings of the National Academy of Sciences.
Until this study, the significance of pleiotrophin (PTN) expression in breast cancer had not been clearly established. These new findings could lead to a better understanding of the molecular pathogenesis of breast cancer and focus attention on PTN and its signaling pathway as possible targets for new cancer therapies.
The study also found that the expression of pleiotrophin activated surrounding cells to remodel the tumor microenvironment, induced tumor angiogenesis, and increased the number of receptors for different markers of aggressive breast cancers.
Breast cancers progress through stages of increasing malignancy triggered by mutations that promote their growth, said Thomas Deuel, the Scripps Research scientist whose laboratory made the discovery. The major finding of our study demonstrates both in vivo and in vitro that inappropriate expression of PTN not only promotes breast cancer progression but that by itself PTN secretion from human breast cancer cells may be sufficient to shift that progression to a more aggressive form of breast cancer.
In the study, three models were tested to determine if inappropriate expression of PTN alone was sufficient to induce breast cancer or whether the cytokine cooperates with different pathogenic mechanisms to stimulate breast cancer progression.
The new study identified PTN as one factor that activates stromal cells-cells found in the loose connective tissue-and induces several features of aggressive breast cancer. While the importance of these cancer cell-stromal cell interactions is well established, only limited progress has been made in identifying the factors that cause stromal cells to initiate tumor progression.
Our breakthrough findings demonstrate that PTN-activated stromal cells are responsible for the ultimat
Contact: Keith McKeown
Scripps Research Institute